Figure 1.

Adapted from Konkalmatt et al.’s study utilizing a CSP-targeting AAV2 vector (AAV-PTP) to selectively target gene delivery to PDAC tumors in vivo [18]. (A) Bioluminescence imaging of mice with subcutaneous PDAC tumors on day 14 after administration with AAV-PTP or wild-type AAV2 capsids harboring a luciferase reporter genome. AAV-PTP was predominantly localized to tumors with minimal activity in other regions. The white circles denote the site of tumors. (B) AAV-PTP’s selectivity for tumors was confirmed by measuring luciferase activity in major organs and tumors. * p < 0.05 comparing AAV2 and AAV-PTP in specified tissue.